For type 2 diabetes mellitus. ANDA 217631, held by Laurus. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 217631 (Metformin Hydrochloride), held by Laurus, was first approved by FDA on Oct 5, 2023, with 2 approved supplements and 0 published complete response letters.
Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 5, 2023 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 5, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 5, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters